Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis

Psoriasis

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis

JAMA Dermatol.

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M

doi: 10.1001/jamadermatol.2019.4029.

Psoriasis

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

J Eur Acad Dermatol Venereol.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB

doi: 10.1111/jdv.15258.

Psoriasis

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis

Br J Dermatol.

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH

doi: 10.1111/bjd.19325.

Psoriasis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Br J Dermatol.

Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group

doi: 10.1111/bjd.19509.

Psoriasis

Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland

Br J Dermatol.

Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern R, Naldi L; Psonet Network

doi: 10.1111/bjd.16715.

Psoriasis

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

J Eur Acad Dermatol Venereol.

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB

doi: 10.1111/jdv.15277.

Atopic Dermatitis

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis

JAMA Dermatol.

Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Küster D, Siegels D, Schmitt J, Flohr C

doi: 10.1001/jamadermatol.2020.0796.

Psoriasis

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis

Br J Dermatol.

Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L

doi: 10.1111/bjd.18634.

RECOMMENDED

Psoriasis

Factors Predicting Persistence of Biologic Drugs in Psoriasis: A Systematic Review and Meta-Analysis

Br J Dermatol.

Mourad A, Straube S, Armijo-Olivo S, Gniadecki R

doi: 10.1111/bjd.17738.

Related content

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis

Factors Predicting Persistence of Biologic Drugs in Psoriasis: A Systematic Review and Meta-Analysis